Donor lymphocyte infusions: An experience from a tertiary care center of North India
Donor lymphocyte infusions (DLIs) are often recommended products after allogeneic hematopoietic stem cell transplant to increase graft – versus – leukemia effect. More success rate of DLI has been reported in relapsed posttransplant chronic myeloid leukemia. Whatever the indication for DLI, mortalit...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Asian Journal of Transfusion Science |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ajts.ajts_211_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593724765372416 |
|---|---|
| author | Divjot Singh Lamba Parmatma Prasad Tripathi Rekha Hans Alka Khadwal Ratti Ram Sharma |
| author_facet | Divjot Singh Lamba Parmatma Prasad Tripathi Rekha Hans Alka Khadwal Ratti Ram Sharma |
| author_sort | Divjot Singh Lamba |
| collection | DOAJ |
| description | Donor lymphocyte infusions (DLIs) are often recommended products after allogeneic hematopoietic stem cell transplant to increase graft – versus – leukemia effect. More success rate of DLI has been reported in relapsed posttransplant chronic myeloid leukemia. Whatever the indication for DLI, mortality related to post-DLI infusion is 5%–20%, and more than one-third of patients will develop acute and/or chronic graft versus host disease (GVHD) after DLI. We report two cases where DLIs were used for residual disease after posttransplant. Both of DLI went uneventful. None of the patient’s developed signs of GVHD postinfusion. Although both patients expired with different causes, none were related to DLI infusion. Information from published literature suggests that DLI should be administered early after relapse or as a prophylactic strategy in patients receiving T-cell-depleted grafts, and patients with aggressive diseases may benefit from disease reduction before DLI. However, further evidence is required to evaluate its efficacy, especially in relapsed or residual hematological malignancies. |
| format | Article |
| id | doaj-art-3e84de71a16d41b7956fb0355ef96b6f |
| institution | Kabale University |
| issn | 0973-6247 1998-3565 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Asian Journal of Transfusion Science |
| spelling | doaj-art-3e84de71a16d41b7956fb0355ef96b6f2025-01-20T09:40:10ZengWolters Kluwer Medknow PublicationsAsian Journal of Transfusion Science0973-62471998-35652024-01-0118112412710.4103/ajts.ajts_211_23Donor lymphocyte infusions: An experience from a tertiary care center of North IndiaDivjot Singh LambaParmatma Prasad TripathiRekha HansAlka KhadwalRatti Ram SharmaDonor lymphocyte infusions (DLIs) are often recommended products after allogeneic hematopoietic stem cell transplant to increase graft – versus – leukemia effect. More success rate of DLI has been reported in relapsed posttransplant chronic myeloid leukemia. Whatever the indication for DLI, mortality related to post-DLI infusion is 5%–20%, and more than one-third of patients will develop acute and/or chronic graft versus host disease (GVHD) after DLI. We report two cases where DLIs were used for residual disease after posttransplant. Both of DLI went uneventful. None of the patient’s developed signs of GVHD postinfusion. Although both patients expired with different causes, none were related to DLI infusion. Information from published literature suggests that DLI should be administered early after relapse or as a prophylactic strategy in patients receiving T-cell-depleted grafts, and patients with aggressive diseases may benefit from disease reduction before DLI. However, further evidence is required to evaluate its efficacy, especially in relapsed or residual hematological malignancies.https://journals.lww.com/10.4103/ajts.ajts_211_23bone marrow transplantationcd3 + cellscellular therapydonor lymphocyte infusionminimal residual disease |
| spellingShingle | Divjot Singh Lamba Parmatma Prasad Tripathi Rekha Hans Alka Khadwal Ratti Ram Sharma Donor lymphocyte infusions: An experience from a tertiary care center of North India Asian Journal of Transfusion Science bone marrow transplantation cd3 + cells cellular therapy donor lymphocyte infusion minimal residual disease |
| title | Donor lymphocyte infusions: An experience from a tertiary care center of North India |
| title_full | Donor lymphocyte infusions: An experience from a tertiary care center of North India |
| title_fullStr | Donor lymphocyte infusions: An experience from a tertiary care center of North India |
| title_full_unstemmed | Donor lymphocyte infusions: An experience from a tertiary care center of North India |
| title_short | Donor lymphocyte infusions: An experience from a tertiary care center of North India |
| title_sort | donor lymphocyte infusions an experience from a tertiary care center of north india |
| topic | bone marrow transplantation cd3 + cells cellular therapy donor lymphocyte infusion minimal residual disease |
| url | https://journals.lww.com/10.4103/ajts.ajts_211_23 |
| work_keys_str_mv | AT divjotsinghlamba donorlymphocyteinfusionsanexperiencefromatertiarycarecenterofnorthindia AT parmatmaprasadtripathi donorlymphocyteinfusionsanexperiencefromatertiarycarecenterofnorthindia AT rekhahans donorlymphocyteinfusionsanexperiencefromatertiarycarecenterofnorthindia AT alkakhadwal donorlymphocyteinfusionsanexperiencefromatertiarycarecenterofnorthindia AT rattiramsharma donorlymphocyteinfusionsanexperiencefromatertiarycarecenterofnorthindia |